絞り込み

16555

広告

温暖化でビール高値に 大麦の収穫減で - 毎日新聞

温暖化でビール高値に 大麦の収穫減で毎日新聞地球温暖化がこのまま進むと大麦の収穫量が減り、今世紀後半にはビールの値段が2倍以上になってしまうかも--。こんな予測...

  1. 温暖化でビール高値に - 徳島新聞
  2. 温暖化でビール高値に (デイリースポーツ...
  3. 温暖化でビール高値に 大麦の収穫減、今世...
  4. 温暖化でビール高値に 大麦の収穫減、今世...

ニュース一覧

Adoptive Cell Therapy in Multiple Myeloma.

著者 Vallet S , Pecherstorfer M , Podar K
Expert Opin Biol Ther.2017 Aug 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (125view , 0users)

Full Text Sources

Medical

Recent breakthrough advances in Multiple Myeloma (MM) immunotherapy have been achieved with the approval of the first two monoclonal antibodies, elotuzumab and daratumumab. Adoptive cell therapy (ACT) represents yet another, maybe the most powerful modality of immunotherapy, in which allogeneic or autologous effector cells are expanded and activated ex vivo followed by their re-infusion back into patients. Infused effector cells belong to two categories: naturally occurring, non-engineered cells (donor lymphocyte infusion, myeloma infiltrating lymphocytes, deltagamma T cells) or genetically- engineered antigen-specific cells (chimeric antigen receptor T or NK cells, TCR-engineered cells). Areas covered: This review article summarizes our up-to-date knowledge on ACT in MM, its promises, and upcoming strategies to both overcome its toxicity and to integrate it into future treatment paradigms. Expert opinion: Early results of clinical studies using CAR T cells or TCR- engineered T cells in relapsed and refractory MM are particularly exciting, indicating the potential of long-term disease control or even cure. Despite several caveats including toxicity, costs and restricted availability in particular, these forms of immunotherapy are likely to once more revolutionize MM therapy.
PMID: 28857616 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード